The most commonly prescribed GLP-1 RAs are: Semaglutide: Ozempic (type 2 diabetes), Wegovy (weight loss) Tirzepatide: Mounjaro (type 2 diabetes), Zepbound (weight loss) Dulaglutide: Trulicity (type 2 diabetes) Liraglutide: Victoza (type 2 diabetes), Saxenda (weight loss) According to the Endocrine Society, GLP-1 RAs promote early satiety, reduce food intake, and are associated with weight loss ( Endocr Pract , 2022)
However, this does not mean eating watermelon can replace current medical treatments
Delayed treatment may lead to hospitalization, malnutrition, or the need for feeding tubes
They serve different patient populations, and sometimes they work well together
The peptide helps return the body to functional training levels faster than traditional rest alone